Additional file 1 of Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Table S1 Patient demographics and characteristics by preceding study at the extension study baseline (SAF). Table S2 Peficitinib treatment exposure and changes in peficitinib dose during the overall period, by preceding study (SAF). Fig. S1 Patient flow through the study, by preceding study. Fig. S2 Response rates by preceding study: a ACR20, b ACR50, c ACR70 over time (FAS). Fig. S3 Mean changes from the baselines of the preceding studies in a TJC68, b SJC66, c SGAP, d SGA, e PGA, and f HAQ-DI (FAS). Fig. S4a Mean changes from the baselines of the preceding studies in DAS28-CRP, by preceding study; b proportion of patients achieving DAS28-CRP